Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 248 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Obesity; Drug Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication

NCT07806838
View directory record Official record
Conditions
Obesity & Overweight, Muscle Mass and Strength, Muscle Function
Interventions
Whey Protein Supplementation, Maltodextrin Placebo Capsules, Mixed Spice Capsules
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Ethambutol Drug Concentrations

NCT01048697
View directory record Official record
Conditions
Obesity, Tuberculosis
Interventions
Ethambutol
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 14, 2026, 8:55 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

NCT07013643
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 14, 2026, 8:55 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Abriendo Caminos 2: Clearing the Path to Hispanic Health

NCT03505658
View directory record Official record
Conditions
Obesity, Childhood Obesity, Nutrient; Excess, Community Health Education
Interventions
Education and Behavior
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
6 Years to 18 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
4
States / cities
Fresno, California • Urbana, Illinois • Ames, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

NCT06186622
View directory record Official record
Conditions
Healthy, Obese, Overweight
Interventions
Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, Midazolam, Sodium Bicarbonate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Not applicable Interventional

Virtual Lifestyle Medicine Comparative Effectiveness Research

NCT03731481
View directory record Official record
Conditions
Chronic Disease, Obesity, Sleep Disorder, Depression
Interventions
Lifestyle Medicine
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women

NCT02100553
View directory record Official record
Conditions
Healthy
Interventions
CE/BZA, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Phase 4 Interventional

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

NCT05657860
View directory record Official record
Conditions
Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Interventions
Guanfacine Extended Release, Placebo
Drug · Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
6 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 14, 2026, 8:55 PM EDT
Active, not recruiting Not applicable Interventional

Penn Medicine Food Market Study

NCT06283394
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
Storefront Choice Architecture, Fresh Funds, Loss Framing
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 14, 2026, 8:55 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users

NCT06467604
View directory record Official record
Conditions
Obesity
Interventions
Surveys, Indirect Calorimetry, Body composition, Anthropometrics
Behavioral · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 14, 2026, 8:55 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

NCT07815678
View directory record Official record
Conditions
Obesity
Interventions
ACCG-2671, Placebo
Drug
Lead sponsor
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
25 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
6
States / cities
Cypress, California • Lake Forest, California • Decatur, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 14, 2026, 8:55 PM EDT
Not yet recruiting Not applicable Interventional

Nutrition Intervention Optimization to Better Utilize Resources and Support Health

NCT07713836
View directory record Official record
Conditions
Diabete Type 2, Obesity & Overweight, Nutritional Intervention, Food Insecurity
Interventions
Meal kits, No-prep meals, Culinary nutrition classes, Text messages
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Phase 4 Interventional Results available

Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment

NCT03779048
View directory record Official record
Conditions
Obesity
Interventions
Behavioral Treatment, Placebo, Phentermine 15 MG
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 70 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Phase 3 Interventional

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

NCT06584916
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 14, 2026, 8:55 PM EDT
Withdrawn Phase 4 Interventional

Treating Toddler Obesity by Treating the Parent/Caregiver Obesity With Weight Loss Medications

NCT06768320
View directory record Official record
Conditions
Weight Loss, Obesity, Childhood, Obesity
Interventions
Lomaira 8Mg Tablet
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
12 Months to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess S-309309 in Healthy and Obese Participants

NCT05247970
View directory record Official record
Conditions
Obesity
Interventions
S-309309, Midazolam, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 14, 2026, 8:55 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

NCT07508241
View directory record Official record
Conditions
Obesity, Overweight and/or Obesity, Overweight, Drug Interaction
Interventions
PF-08653944, Acetaminophen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

NCT03818256
View directory record Official record
Conditions
Antipsychotic-induced Weight Gain (AIWG)
Interventions
Miricorilant, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 14, 2026, 8:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation

NCT00388180
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidaemias, Obesity
Interventions
GW501516, GW590735
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Not applicable Interventional

Exercise is Medicine at Emory Seavey Internal Medicine Clinic

NCT03416634
View directory record Official record
Conditions
Physical Activity
Interventions
App, Wearable Device, Automated Motivational Message, Personalized Motivational Message
Behavioral
Lead sponsor
Emory University
Other
Eligibility
20 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Phase 4 Interventional Results available

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

NCT05548647
View directory record Official record
Conditions
Obesity
Interventions
Behavioral Treatment, Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Randomized Study to Evaluate the Effect of an Investigational Product on Weight Loss and Body Composition

NCT01272739
View directory record Official record
Conditions
Obesity
Interventions
IHBG-10, Placebo
Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

NCT04881760
View directory record Official record
Conditions
Obesity, Overweight
Interventions
LY3437943, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
25
States / cities
Scottsdale, Arizona • Anaheim, California • Fresno, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 14, 2026, 8:55 PM EDT
Completed Phase 2 Interventional

Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes

NCT00067626
View directory record Official record
Conditions
Obesity, Pre-diabetes, Insulin Resistance, Impaired Glucose Tolerance, Impaired Fasting Glucose
Interventions
Chromium
Dietary Supplement
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 14, 2026, 8:55 PM EDT